Review : Purine nucleoside analogs: fludarabine,entostatin and cladribine

Abstract

Get full access to this article

View all access options for this article.

References

Product information, Leustatin™, Ortho Biotech Inc., Raritan, NJ, 1993.

Tallman MS , Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood. 1995;86: 2463-2474.

Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340: 952-956.

Avery TL , Rehg JE , Lumm WC , et al. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res. 1989:4972- 4978.

Beutler E. , Piro LD , Saven A. , et al. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma. 1991;5:1-8.

Orr RM , Talbot DC , Aherne GW , et al. 2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines. Clin Cancer Res. 1995;1:391-398.

Carson DA , Wasson DB , Taetle R. , et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983 ;62:737-743.

Piro LD 2-Chlorodeoxyadenosine: drug development priorities. J Clin Oncol. 1992;10:1507-1510.

Carrera CJ , Terai C. , Piro L. , et al. 2-CdA chemotherapy triggers programmed cell death in normal and malignant lymphocytes. J Purine Pyrimidine Res. 1991;2(Suppl 1):38.

10.

Seto S. , Carrera CJ , Kubota M. , et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75:377-383.

11.

Robertson LE , Chubb S. , Meyn R. , et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine . Blood. 1993;81:143-150.

12.

Kawasaki H. , Carrera CJ , Piro LD , et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine . Blood. 1993;81:597-601.

13.

Piro LD 2-Chlorodeoxyadenosine treatment of lymphoid malignancies. Blood. 1992;79:843-845.

14.

Carrera CJ , Yamanaka H. , Piro LD , et al. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. Adv Exp Med Biol . 1989:253b.

15.

Petzer AL , Bilgeri R. , Zilian U. , et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood. 1991;78:2583-2587.

16.

Hutton JJ , von Hoff DD Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay . Cancer Drug Deliv. 1986; 3:115-122.

17.

Liliemark J. , Albertioni F. , Hassan M. , et al. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration . J Clin Oncol. 1992 ;10:1514 -1518.

18.

Saven A. , Cheung WK , Smith I. , et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol. 1996;14:978-983.

19.

Albertioni F. , Juliusson G. , Liliemark J. On the bioavailability of 2-chlorodeoxyadenosine (2-CdA): the influence of food and omeprazole. Eur J Clin Pharmacol. 1993;44:579-582.

20.

Carson DA , Wasson DB , Esparza LM , et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2-deoxyadenosine . Proc Natl Acad Sci USA. 1992;89:2970 -2974.

21.

Liliemark J. , Juliusson G. On the pharmacokinetics of 2-chloro-2'deoxyadenosine in humans. Cancer Res. 1991;51:5570-5572.

22.

Liliemark J. , Juliusson G. On the pharmacokinetics of 2-chloro-2'deoxyadenosine (CdA) in cerebrospinal fluid (CSF). Blood. 1992; 80(Suppl 1):471a.

23.

Liliemark J. , Petterson B. , Juliusson G. The relationship between plasma 2-chlorodeoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent and continuous IV infusion in patients with chronic lymphocytic leukemia. Blood. 1991;78(Suppl):33a.

24.

LiliemarkJ. , Juliusson G. Cellular pharmacokinetics of 2-chloro-2'deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clinical Cancer Res. 1995;1:385-390.

25.

Marks RS , Richardson RL , Reid JM , et al. A phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 1994;13:155. Abstract 416.

26.

Estey EH , Kurzrock R. , Kantarjian HM , et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-ODA). Blood. 1992;79: 882-887.

27.

Weiss GR , Kuhn JG , Smith LS , et al. A phase I trial and pharmacokinetic study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemo Pharmacol. 1995;35(5):397-402.

28.

Santana VM , Mirro J.Jr , Harwood FC , et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol. 1991;9:416-422.

29.

Kearns CM , Blakley RL , Santana VM , et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994;54:1235-1239.

30.

Spielberger RT , O'Brien S. , Ratain MJ , et al. Phase I study of 2-chlorodeoxyadenosine in hematologic malignancies. Blood. 1992;80:1831a.

31.

Kornblau SM , Gandhi V. , Andreeff HM , et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10:1563-1569.

32.

Larson RA , Mick R. , Spielberger RT , et al. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol. 1996;14:188- 195.

33.

Tefferi A. , Witzig TE , Reid JM , et al. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol. 1994;12:569- 574.

34.

Saven A. , Kawasaki H. , Carrera CJ , et al. 2-Chlorodeoxyadenosine dose escalation in non-hematologic malignancies . J Clin Oncol. 1993;11:671- 678.

35.

Kobayashi K. , Vogelzang NJ , O'Brien S. , et al. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994;74:168-173.

36.

Faguet GB Chronic lymphocytic leukemia: an updated review. J Clin Oncol. 1994;12:1974-1990.

37.

Piro LD , Carrera CJ , Beutler E. , et al. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988 ;72:1069-1073.

38.

Juliusson G. , Liliemark J. High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol. 1993;11:679- 689.

39.

Saven A. , Carrera CJ , Carson DA , et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph. 1991;5(Suppl):133-138.

40.

Tallman MS , Hakimian D. , Zanzig C. , et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 1995;13:983-988.

41.

Juliusson G. , Elmhorn-Rosenborg A. , Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1992 ;327:1056-1061.

42.

Delannoy A. , Hanique G. , Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine . N Engl J Med. 1993;328:812. Letter.

43.

Saven A. , Lemon RH , Piro LD 2- Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1993 ;328:812-813. Letter.

44.

O'Brien S. , Kantarjian H. , Estey E. , et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med. 1994; 330:319-322.

45.

Saven A. , Lemon RH , Kosty M. , et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570-574.

46.

Juliusson G. , Christiansen I. , Hansen MM , et al. Oral cladribine as primary therapy for symptomatic chronic lymphocytic leukemia (CLL). J Clin Oncol. 1996;14:2160 - 2166.

47.

Dellanoy A. , Martiat P. , Gala JL , et al. 2-Chlorodeoxyadenosine (CdA) for patients with B-cell chronic lymphocytic leukemia. Leukemia. 1995;9:1130-1135.

48.

Saven A. , Piro LD Treatment of hairy cell leukemia. Blood. 1992 ;79:1111-1120.

49.

Piro LD , Carrera CJ , Carson DA , et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.

50.

Piro LD , Saven A. , Ellison D. , et al. Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol. 1992;11:846a.

51.

Estey EH , Kurzrock R. , Kantarjian HM , et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 1992;79: 882-887.

52.

Lauria F. , Benfenati D. , Raspadori D. , et al. 2-Chlorodeoxyadenosine in the treatment of patients with hairy cell leukemia. Blood. 1991;79(Suppl 1):34a.

53.

Juliusson G. , Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood. 1992;79:888-894.

54.

Tallman MS , Hakimian D. , Variakojis D. , et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80: 2203-2209.

55.

Tallman MS , Hakimian D. , Rademaker AW , et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood. 1996;88:1954- 1959.

56.

Saven A. , Piro LD Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin. Ann Intern Med. 1993;119:278-283.

57.

Cheson BD Infectious and immunosuppressive complications of purine analog therapy . J Clin Oncol. 1995;13:2431-2448.

58.

Juliusson G. , Heldal D. , Hippe E. , et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995;13:989-995.

59.

Hakimian D. , Tallman MS , Kiley C. , et al. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1993;82: 1798-1802.

60.

Wheaton S. , Tallman MS , Hakimian D. , et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood. 1996 187:1556-1560.

61.

Cancer Facts and Figures. Atlanta, Ga: American Cancer Society; 1997.

62.

Kay AC , Saven A. , Carrera CJ , et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992;10:371-377.

63.

Hoffman M. , Tallman MS , Hakimian D. , et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:788-792.

64.

Hickish T. , Serafinowski P. , Cunningham D. , et al. 2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer. 1993;67:139-143.

65.

Khan A. , Schiller G. , Levine A. , et al. 2-Chloro-2'-deoxyadenosine (2-CdA), an active agent in the treatment of advanced relapsed or refractory low to intermediate grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol. 1994;13:386. Abstract 1315.

66.

Saven A. , Lee T. , Kosty M. , et al. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:2139 -2144.

67.

Saven A. , Emanuele S. , Kosty M. , et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995 ;86:1710-1716.

68.

Canfield V. , Baughman C. , Vose J. A phase II trial of 2-chlorodeoxyadenosine (2-CdA) in previously untreated patients (pts) with low grade non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol. 1994 ;13:381. Abstract 1292.

69.

Saven A. , Carrera CJ , Carson DA , et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. 1992;80:587-592.

70.

Kuzel TM , Hurria A. , Samuelson E. , et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood. 1996;87:906-911.

71.

O'Brien S. , Kurzrock R. , Duvic M. , et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994;84:733-738.

72.

Santana VM , Mirro J.Jr , Kearns C. , et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10:364 -370.

73.

Santana VM , Hurwitz CA , Blakley RL , et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood. 1994 ;84:1237-1242.

74.

Vahdat L. , Wong ET , Wile MJ , et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994;84:3429-3434.

75.

Van den Neste E. , Ferrant A. , Delannoy A. , et al. 2-Chloro-deoxyadenosine with or without daunorubicin for relapsing or refractory acute myeloblastic leukemia. Blood. 1993;82(Suppl 1):503a.

76.

Saven A. , Piro LD , Lemon RH , et al. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer. 1994;73:2953-2963.

77.

Dann EJ , Anastasi J. , Larson RA High dose cladribine (2CDA) therapy for chronic myelogenous leukemia in blast phase (CML-BP). Blood. 1996;88(Suppl 1):235a.

78.

Dimopoulos MA , Kantarjian H. , Estey E. , et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med. 1993;118:195-198.

79.

Dimopoulos MA , Kantarjian H. , Wever D. , et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994;12:2694-2698.

80.

Dimopoulos MA , Weber DM , Kantarjian H. , et al. 2-Chlorodeoxyadenine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994;5:288-289.

81.

Pless M. , Gratwohl A. , Fichelli A. , et al. 2-Chloro-deoxyadenosine as treatment of severe acute graft versus host disease. Blood. 1993; 82(Suppl 1):1667a.

82.

Sipe JC , Romine JS , Koziol JA , et al. Cladribine in treatment of chronic progressive multiple sclerosis . Lancet. 1994;344:9-13.

83.

Ryba M. , Grieb P. , Pastuszko M. , et al. Successful prevention of neurological deficit in SAH patients with 2-chlorodeoxyadenosine. Acta Neurochir. 1993;124:61- 65.

84.

Cheson BD , Vena DA , Foss FM , Sorensen JM Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994;12:2216-2228.

85.

Kobayashi K. , Vogelsang NJ , O'Brien SM , et al. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994;74:168-173.

86.

Dann EJ , Gillis S. , Polliack A. , et al. Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J med. 1993;329: 1547-1548.

87.

Cardinale V, ed. Red Book . Montvale, NJ: Medical Economics ; 1996.